
<DOC>
<DOCNO>WT02-B26-62</DOCNO>
<DOCOLDNO>IA008-000083-B005-349</DOCOLDNO>
<DOCHDR>
http://www.nami.org:80/research/researj.htm 38.250.129.71 19970222102038 text/html 3111
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 10:19:07 GMT
Server: Apache/1.0.5
Content-type: text/html
</DOCHDR>
<html>
<HEAD>
<TITLE>Do Neuroleptics Help Negative Symptoms?</TITLE>
</HEAD>
<body    bgcolor="#ffffff"  text="#000000"  link="#0000ee" vlink="551a8b" alink="ff0000">

<center>

<H6><I>

<A HREF = "/index.html" target="_top">NAMI</A> /

<A HREF="/about.htm">About</A> /

<A HREF="/book.htm">Books</A> /

<A HREF="/confer.htm">Conferences</A> /

<A HREF="/outlook.htm">Outlook</A> /

<A HREF="/medical.htm">Medical</A> /

<A HREF="/update.htm">Updates</A>

</H6><A HREF="/index.html" target="_top">

<p align=center><img src="/graphics/blulogo3.gif" align=middle border=0> </p></a></h6>

<h6>

<A HREF = "mailto:barbara@nami.org,namiofc@aol.com">Comment</A> /

<A HREF="/help.htm">Help</A> /

<A HREF="/toc.htm">Index</A> /

<A HREF="/joinform.htm">Membership</A> /

<A HREF="/noframes.htm" TARGET="_top">Noframes</A> /

<A HREF="/search.htm">Search</A> /

<A HREF="/stats">Statistics</A>

</H6>

</I></center>
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->

<hr>


<H2>Do Neuroleptics Help Negative Symptoms?</H2>
<HR>



	Positron emission tomography (PET) scans can monitor the effects of antipsychotic medication by visualizing the regions in the 
brain where the drugs block dopamine receptors.  In a report by Wolkin et al published in the March 1996 issue of the American Journal of 
Psychiatry, the researchers hypothesized that patients with schizophrenia with prominent negative symptoms would have a poorer response 
to treatment with the neuroleptic haloperidol.  They compared cerebral glucose metabolism in patients with schizophrenia before and after 
haloperidol treatment.  While haloperidol caused a decrease in prefrontal glucose metabolism and an increase in basal ganglia, this response 
was blunted in the patients with prominent negative symptoms (withdrawal, social problems, lack of energy, lack of concern about personal 
appearance, reduced ability to express emotion).  These patients also performed worse on tests of cognitive ability than those with less severe 
negative symptoms, whose scores improved after treatment.
<p>
	These results suggest that patients with prominent negative symptoms may have a poorer response to neuroleptic treatment because 
of differences in brain metabolism.
<hr><h6>
<p align=center><a href="/poc.htm">CONTACT</a> | <a href="/joinform.htm">MEMBERSHIP</a> | <a href="mailto:barbara@nami.org">WEBMASTER</a></p></h6>
<P><P>
<center><H6>Copyright &copy 1996 <a href="/index.html" target=_top>National Alliance for the Mentally Ill</a> - All Rights Reserved</H6>
</center></body>




























































































































































</html>

</DOC>